(Q38761495)

6 September 2017

title

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis (English)

1 reference

6 September 2017

Benedikt Kretzschmar

1

1 reference

6 September 2017

Hannah Pellkofer

series ordinal

2

1 reference

6 September 2017

Martin S Weber

series ordinal

3

1 reference

6 September 2017

publication date

1 April 2016

1 reference

Current Neurology and Neuroscience Reports

6 September 2017

published in

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

38

1 reference

Azathioprine for multiple sclerosis

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Cyclophosphamide for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Methotrexate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Role of immunosuppressive therapy for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Fingolimod-associated macular edema: incidence, detection, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Teriflunomide and its mechanism of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Safety evaluation of leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Leflunomide-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Defining a role for laquinimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Molecular mechanisms underlying the effects of statins in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Drug Insight: using statins to treat neuroinflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Statins in the treatment of central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-016-0639-4

PML in a patient treated with fumaric acid

21 January 2018

1 reference

12 December 2020

Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Therapeutic decisions in multiple sclerosis: moving beyond efficacy

1 reference

12 December 2020

Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).

1 reference

12 December 2020

PML in a patient with lymphocytopenia treated with dimethyl fumarate

1 reference

12 December 2020

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine

1 reference

12 December 2020

Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients

1 reference

12 December 2020

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

1 reference

12 December 2020

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

1 reference

12 December 2020

10.1007/S11910-016-0639-4

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1008096355

0 references

1 reference